Androgen deprivation therapy (ADT) has been the standard of care for metastatic prostate cancer since 1941, when Huggins and Hodges 1 demonstrated the effect of androgens on prostate cancer and the impact of orchiectomy on bone pain symptoms. Hot
Search Results
Miren Gaztañaga and Juanita Crook
. Both trials closed prematurely but are in the follow-up period and will combine their data on more than 350 patients. Table 2 Summary of Level 1 Evidence for Androgen Deprivation Therapy in High-Risk Patients Once ADT has been initiated
Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian
, (E) IHD, and (F) aggregate CVD (any of 5 outcomes) with and without prior CVD, stratified by ADT type. Abbreviations: ADT, androgen deprivation therapy; CHF, chronic heart failure; CVD, cardiovascular disease; GnRH, gonadotropin-releasing hormone
Jason Hu, Armen G. Aprikian, Marie Vanhuyse, and Alice Dragomir
important aspect to consider. Androgen deprivation therapy (ADT) is a cornerstone of advanced PCa treatment, and it is estimated that nearly 1 in 2 patients with PCa will receive some form of ADT during their disease course. 3 , 4 The role of ADT is strongly
Brandon A. Mahal, Ming-Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, and Anthony V. D'Amico
the study cohort, stratified by PSA-DT and PSA level at the time of salvage ADT. PSA-DT Figure 1. CONSORT diagram. Abbreviations: 3D-CRT, 3D conformal radiation therapy; ADT, androgen deprivation therapy; LHRH, luteinizing hormone
Philip J. Saylor and Matthew R. Smith
/print certificate. Learning Objectives Upon completion of this activity, participants will be able to: • Identify clinical scenarios in which androgen deprivation therapy (ADT) is most useful in the treatment of prostate cancer • Describe
U-Syn Ha, Jin Bong Choi, Jung Im Shim, Minjoo Kang, Eunjung Park, Shinhee Kang, Jooyeon Park, Jangmi Yang, Insun Choi, Jeonghoon Ahn, Cheol Kwak, Chang Wook Jeong, Choung Soo Kim, Seok-Soo Byun, Seong Il Seo, Hyun Moo Lee, Seung-Ju Lee, Seung Hwan Lee, Byung Ha Chung, and Ji Youl Lee
Background Although major groups or guidelines do not recommend primary androgen deprivation therapy (PADT) as primary treatment of nonmetastatic prostate cancer, 1 , 2 a considerable number of physicians have used PADT for nonmetastatic prostate
James L. Mohler
The strategic application of androgen deprivation therapy (ADT) in the clinic is still evolving, according to James L. Mohler, MD, Chair of the Department of Urology and Associate Director of Translational Research, Roswell Park Cancer Institute
Dennis R. Taaffe, Robert U. Newton, Nigel Spry, David J. Joseph, and Daniel A. Galvão
Background Androgen deprivation therapy (ADT) is used extensively in the management of localized and advanced prostate cancer (PCa). 1 Although effective in delaying disease progression and enhancing survival, 1 , 2 ADT is associated with an array
Masaki Shiota
Since the work of Huggins and Hodges in the mid 1900s, primary androgen deprivation therapy (PADT) has been the backbone therapy for metastatic prostate cancer. It has recently been combined with upfront docetaxel or abiraterone. Although PADT
